Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Treatment Patterns and Outcomes in HR+, HER2- Metastatic Breast Cancer Patients Treated With CDK 4/6 Inhibition in the First Line (1L) Setting

NCT07512063 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07512063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07512063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Treatment Patterns and Outcomes in HR+, HER2- Metastatic Breast Cancer Patients Treated With CDK 4/6 Inhibition in the First Line (1L) Setting
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
October 8, 2024
Completion date
March 17, 2025
Enrollment
480 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer